[eDisclosure Notice] KOSDAQ - 4 Days

◆Optipharm= Acquired patent rights related to 'Transgenic cloned pigs for xenotransplantation with knockout of pig endogenous retrovirus Envelope C negative, GGTA1, CMAH, iGb3s, β4GalNT2 genes, and expression of human CD46 and TBM genes, and method for producing the same.'

◆Digital Daesung= Decided to merge Hanuri Open Education and Gangnam Daesung Dormitory Academy.

◆Oi Solution= On a consolidated basis, Q3 operating profit was preliminarily estimated at 5 billion KRW, down 74.7% from the same period last year. Sales for the same period decreased by 50.3% to 30.2 billion KRW.

◆Alteogen= Decided on a third-party allotment paid-in capital increase worth 30 billion KRW.

◆Korea Exchange= The KOSDAQ Market Committee reviewed and resolved to delist Kolon TissueGene.